{"id":25964,"date":"2023-05-02T08:33:56","date_gmt":"2023-05-02T08:33:56","guid":{"rendered":"https:\/\/gateway.ventures\/startups\/mk2-biotechnologies-2\/"},"modified":"2023-05-03T14:47:40","modified_gmt":"2023-05-03T14:47:40","slug":"mk2-biotechnologies-2","status":"publish","type":"startups","link":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/","title":{"rendered":"MK2 Biotechnologies"},"author":16,"featured_media":25958,"template":"","meta":[],"startup_status":[36],"investment_focus":[],"class_list":["post-25964","startups","type-startups","status-publish","has-post-thumbnail","hentry","startup_status-funded-en"],"acf":{"logo":25950,"show_stage":["Yes"],"stage":"Pre Series-A","show_niche":["Yes"],"niche":"BioTech","closing_month_year":"May 2023","female_founder":"","location":"Planegg,DE","website":"https:\/\/www.mk2.bio","demo_video_url":"","meet-up_lp_link":"https:\/\/calendly.com\/gatewayventures\/mk2-gateway-investor-founder-meetup?month=2023-05","calendly_code":"https:\/\/calendly.com\/gatewayventures\/mk2-gateway-investor-founder-meetup?month=2023-05","calendly_code_Kopie":"","oneline_description":"Bioactive Peptides & Proteins for Mass Applications","description":"","problem":"The use of synthesised peptides &amp; proteins is attractive in various areas of application like\r\n<ul>\r\n \t<li><strong>personal care<\/strong> (e.g. anti-aging),<\/li>\r\n \t<li><strong>food &amp; beverages<\/strong> (e.g. flavors, conservation),<\/li>\r\n \t<li><strong>animal breeding<\/strong> (e.g. antibiotics substitutes &amp; vaccines)<\/li>\r\n \t<li>and <strong>crop cultivation<\/strong> (e.g. fungicides, fertilizer substitutes).<\/li>\r\n<\/ul>\r\nEstablished production methods for peptides &amp; proteins are\u00a0<strong>prohibitively expensive at the required purity levels<\/strong>\u00a0due to a lack of scalability.\r\n\r\nRecently, <strong>cultured meat companies<\/strong> are struggling to find possibilities to scale production because of this issue as well","solution":"mk2 Biotechnologies developed a\u00a0<strong>proprietary process<\/strong>\u00a0that allows the\u00a0<strong>scalable and cost-efficient production of high-purity peptides\u00a0and proteins<\/strong> for mass market applications.\r\n\r\nThis innovative and scalable process eliminates the current bottlenecks of established synthesis methods and allows customers' quality requirements to be fully met, while\u00a0<strong>reducing production costs by several orders of magnitude.<\/strong>\u00a0This means that bioactive peptides and proteins can be used for the\u00a0<strong>first time in volume markets<\/strong>\u00a0such as pharmaceuticals, cosmetics, food &amp; beverages and agriculture.\r\n\r\nIn one of its flagship projects, mk2 Biotechnologies is aiming to lower cost in the lab-grown meat industry to enable <strong>price parity between cultured and naturally produced meat.<\/strong>\r\n\r\nmk2 Biotechnologies is able to flexibly and effciently produce petides and proteins to target the known challenges of today, and the unknown ones of tomorrow.","market":"Global market potential of\u00a0<strong>\u20ac 100 billion<\/strong>\u00a0for target peptides over all fields of application - animal health, agriculture, food &amp; beverages, pharmaceuticals and cosmetics.\r\n\r\nThe three entry markets have potentials of <strong>\u20ac 43 billion (Growth Factors in cultured meat), \u20ac 70 billion (Monoclonal Antibody (mAb) Fragments in pharmaceuticals),<\/strong> and <strong>\u20ac 8bn (Aquaculture parasites)<\/strong> respectively.\r\n\r\nAverage growth rates (CAGRs) over all these markets lie <strong>above 10%.<\/strong>","usp":"mk2 Biotechnologies\u2019 approach allows<span class=\"notion-enable-hover\" data-token-index=\"1\">\u00a0<strong>large-scale <\/strong><\/span><strong><span class=\"discussion-id-601b75b9-8586-49c4-b4a5-f5c7cd276a78 notion-enable-hover\" data-token-index=\"2\">peptide &amp; protein <\/span><\/strong><span class=\"notion-enable-hover\" data-token-index=\"3\"><strong>production with high purities and at low cost<\/strong>.<\/span>\u00a0<span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"5\">The mk2 technology toolbox consists of a<\/span><strong><span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"6\"> variety of technologies<\/span><\/strong><span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"7\"> that are combined appropriately. IP exists on cleavage domains, precipitation domains, the combination thereof (fusion proteins) and the process required to purify the target products. Respectively, competitor advantage is achieved by<\/span><strong><span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"8\"> patents and profound undisclosed process know-how<\/span><\/strong><span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"9\"> (process &amp; combination know-how). <\/span><strong><span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"10\">Required granted patents are in-licensed exclusively and supplemented by internally developed patents<\/span><\/strong><span class=\"discussion-id-3aa936f3-53bc-4737-9771-379b7de1e66d notion-enable-hover\" data-token-index=\"11\"> (filed and in filing).<\/span>","business_model":"Based on i)\u00a0<strong>future direct sales<\/strong>\u00a0(charge per unit) and ii)\u00a0<strong>license fees<\/strong>.\r\n\r\nShort-term focus on cooperation-based R&amp;D projects. Once developed, these products will be produced by\u00a0<strong>contract manufacturing organizations (CMO)<\/strong>\u00a0and sold by mk2 Biotechnologies, or produced under respective licenses by the customer themselves. In-house activities will be focused on lab-scale R&amp;D and production only.","traction":"<ul>\r\n \t<li>Exclusive\u00a0<strong>IP license agreements<\/strong><\/li>\r\n \t<li>Scale-up agreement with\u00a0<strong>leading German Contract Manufacturing Organization (CMO)<\/strong>\u00a0in place<\/li>\r\n \t<li>Acquired <strong>more than \u20ac 2 million<\/strong> in non-dilutive public funding<\/li>\r\n \t<li>Already running several active and <strong>successful collaboration projects with partners like Sartorius &amp; Wacker<\/strong><\/li>\r\n \t<li>Pipeline of <strong>4 additional patents<\/strong> to be filed until Q4 2023<\/li>\r\n<\/ul>","exit_potential":"Comparable Exits in the space are promising with <strong>9-figure<\/strong> trade sales in and IPO valuation between <strong>\u20ac 2 billion<\/strong> and <strong>\u20ac 15 billion.<\/strong> mk2\u2019s project partner <strong>Satorius acquired<\/strong> albumin-technology company <strong>Albumedix for \u20ac 500M in 2022.<\/strong>","nrofcoinvestors":"","tm_1_name":"Dr. Konstantinos Antonopoulos","tm_2_name":"Dr. Sebastian Mangold","tm_3_name":"Dr. Marco Giuman ","tm_4_name":"","tm_1_position":"Managing Director","tm_2_position":"Managing Director","tm_3_position":"CTO","tm_4_position":"","image_-_team_member_1":25966,"image_-_team_member_2":25968,"image_-_team_member_3":25970,"image_-_team_member_4":null,"deal_link":"https:\/\/gateway.ventures\/d\/de\/investment-opportunities\/mk2biotechnologies","founder_group_image":null,"why_we_invested_in_this_startup":"","dealcaptain_opinion":"","stoop":"Yes","pb":"No","investment_terms":"<ul>\r\n \t<li>Gateway Ventures CLA bis zu \u20ac 300.000<\/li>\r\n \t<li>Cap: 45M<\/li>\r\n \t<li>Discount: 20%<\/li>\r\n \t<li>Interest: 5% p.a. (non-compounding)<\/li>\r\n \t<li>Closing: End of May<\/li>\r\n \t<li>Laufzeit: 18 Monate<\/li>\r\n \t<li>Round Size up to 1.5M<\/li>\r\n \t<li>min. Ticket \/ Investor: \u20ac 10.000<\/li>\r\n<\/ul>","traction_image":null,"hide_socials":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MK2 Biotechnologies - Gateway Ventures<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MK2 Biotechnologies - Gateway Ventures\" \/>\n<meta property=\"og:url\" content=\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Gateway Ventures\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-03T14:47:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/\",\"url\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/\",\"name\":\"MK2 Biotechnologies - Gateway Ventures\",\"isPartOf\":{\"@id\":\"https:\/\/gateway.ventures\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png\",\"datePublished\":\"2023-05-02T08:33:56+00:00\",\"dateModified\":\"2023-05-03T14:47:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#primaryimage\",\"url\":\"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png\",\"contentUrl\":\"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png\",\"width\":1600,\"height\":300,\"caption\":\"MK2 - Gateway Ventures\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/gateway.ventures\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MK2 Biotechnologies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/gateway.ventures\/#website\",\"url\":\"https:\/\/gateway.ventures\/\",\"name\":\"Gateway Ventures\",\"description\":\"invest. contribute. benefit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/gateway.ventures\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MK2 Biotechnologies - Gateway Ventures","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/","og_locale":"en_US","og_type":"article","og_title":"MK2 Biotechnologies - Gateway Ventures","og_url":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/","og_site_name":"Gateway Ventures","article_modified_time":"2023-05-03T14:47:40+00:00","og_image":[{"width":1600,"height":300,"url":"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/","url":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/","name":"MK2 Biotechnologies - Gateway Ventures","isPartOf":{"@id":"https:\/\/gateway.ventures\/#website"},"primaryImageOfPage":{"@id":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#primaryimage"},"image":{"@id":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#primaryimage"},"thumbnailUrl":"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png","datePublished":"2023-05-02T08:33:56+00:00","dateModified":"2023-05-03T14:47:40+00:00","breadcrumb":{"@id":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#primaryimage","url":"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png","contentUrl":"https:\/\/gateway.ventures\/wp-content\/uploads\/2023\/05\/MK2-2nd-Version-Header.png","width":1600,"height":300,"caption":"MK2 - Gateway Ventures"},{"@type":"BreadcrumbList","@id":"https:\/\/gateway.ventures\/en\/startups\/mk2-biotechnologies-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/gateway.ventures\/"},{"@type":"ListItem","position":2,"name":"MK2 Biotechnologies"}]},{"@type":"WebSite","@id":"https:\/\/gateway.ventures\/#website","url":"https:\/\/gateway.ventures\/","name":"Gateway Ventures","description":"invest. contribute. benefit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/gateway.ventures\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/startups\/25964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/startups"}],"about":[{"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/types\/startups"}],"author":[{"embeddable":true,"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/users\/16"}],"version-history":[{"count":3,"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/startups\/25964\/revisions"}],"predecessor-version":[{"id":25994,"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/startups\/25964\/revisions\/25994"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/media\/25958"}],"wp:attachment":[{"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/media?parent=25964"}],"wp:term":[{"taxonomy":"startup_status","embeddable":true,"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/startup_status?post=25964"},{"taxonomy":"investment_focus","embeddable":true,"href":"https:\/\/gateway.ventures\/en\/wp-json\/wp\/v2\/investment_focus?post=25964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}